Organised by SHC
Singapore Hepatology Conference 2026
ONLINE over 4 evenings
For the Busy Clinician
Singapore Hepatology Conference
To View SHC 2026 Videos and Download PDF Slides:
To view the menu of slides and video recordings from any year, please click on the e-Resources tab.
If you wish to watch videos and download slides of past conferences up to SHC 2022, you must register or log in to the Website. Videos and Slides up to SHC 2022 are available free of charge.
If you had registered as a premium user in 2024, you will continue to have access to 2024 materials.
Singapore Hepatology Conference 2026 Scientific Programme
August, 2026
31
| Programme | Time (SGT) |
|---|---|
| Chronic Hepatitis B And D | |
| Chairs | |
| Opening comments and introduction Prof. Seng Gee Lim, National University Health System, Singapore View Bio |
06.30 pm to 06.40 pm |
| CHB Grey zone: clinical significance Adj Assoc. Prof. Daniel Huang, National University Health System, Singapore View Bio |
|
| Landscape of Hepatitis B cure in 2026 Prof. Man Fung Yuen, Hong Kong University, Hong Kong View Bio |
07.00 pm to 07.20 pm |
| GSK Symposium Integrating qHBsAg Testing into Routine Clinical Practice: Optimizing the Journey Towards Functional Cure in CHB Speaker: Prof. Grace Wong, Chinese University of Hong Kong, Hong Kong,View Bio Moderator: Dr. Tan Poh Seng, PS Tan Digestive & Liver Centre, Singapore, View Bio |
7.20pm to 7.50 pm |
| Q&A | 7.50pm to 8.15pm |
| Break | 8.15 pm to 8.30 pm |
| Gene therapy for CHB Prof. Ed Gane, University of Auckland, New Zealand View Bio |
8.30 pm to 8.50 pm |
| Immune suppression and HBV Prof. Teerha Piratvisuth, Prince of Songkla University, Thailand View Bio |
08.50 pm to 09.10 pm |
| Management of severe hepatitis B Flares Prof. Seng Gee Lim, National University Health System, Singapore View Bio |
09.10 pm to 09.30 pm |
| Delta Hepatitis Update Prof. Pietro Lampertico, University of Milan, Italy View Bio |
09.30 pm to 9.50 pm |
| Q&A | 9.50 pm to 10.15 pm |
| Close | 10.15pm |
September, 2026
1
| Programme | Time (SGT) |
|---|---|
| MASLD & MASH | |
| Opening comments and Introduction Adj. Prof. Mark Muthiah, National University Health System, Singapore View Bio |
06.30pm to 06.45pm |
| Phenotype-genotype interactions in MASLD: A south east asian perspective Prof. Chan Wah Kheong, University of Malaya, Malaysia View Bio |
06.45pm to 07.10pm |
| Screening for MASLD in the community: are our protocols ready? Prof. Neeraj Bhala View Bio |
07.10pm to 07.35pm |
| Q&A | 07.35pm to 08.00pm |
| Break | 08.00pm to 08.20pm |
| Debate: MASLD and MASH has lost its relevance – we should only be screening for fibrosis (con) Prof. Vincent Wong, Chinese University of Hong Kong, Hong Kong View Bio |
08.20pm to 08.40pm |
| Debate: MASLD and MASH has lost its relevance – we should only be screening for fibrosis (pro) Adj. Prof. Mark Muthiah View Bio |
08.40pm to 09.00pm |
| Q&A | 09.00pm to 09.20pm |
| A practical approach to treatment of MASH (pre-recorded) Prof. Jacob George, University of Sydney, Australia View Bio |
09.20pm to 9.45pm |
| Extra-hepatic caridometabolic consequences in MASLD: when to screen Prof. M Shadab Siddiqui, University of Virginia, USA View Bio |
09.45pm to 10.10pm |
| Q&A | 10.10pm to 10.30pm |
September, 2026
2
| Programme | Time (SGT) |
|---|---|
| Hepatocellular carcinoma (HCC) | |
| Opening comments and Introduction Adj. Assoc. Prof. Daniel Huang, National University Health System, Singapore View Bio |
06.30 pm to 06.45 pm |
| Updates in systemic therapy for HCC Prof. Arndt Vogel, Hannover Medical School, Germany View Bio |
06.45 pm to 07.10 pm |
| Conversion therapy for initially unresectable HCC Prof. Masatoshi Kudo, Kindai University, Japan View Bio |
07.10 pm to 07.35 pm |
| HCC risk stratification Prof. Luca Valenti, University of Milan, Italy View Bio |
07.35 pm to 08.00 pm |
| Q&A | 08.00 pm to 08.20 pm |
| Break | 8.20pm to 8.30pm |
| Loco-regional therapy in intermediate HCC Prof. Pierce Chow, Duke-NUS Graduate School of Medicine, Singapore View Bio |
08.30 pm to 08.55 pm |
| Prevention and surveillance for hepatocellular carcinoma in chronic hepatitis B Prof. Grace Wong, Chinese University of Hong Kong, Hong Kong View Bio |
08.55 pm to 09.20 pm |
| MASLD-related HCC: risk prediction, surveillance, and prevention Prof. Leon Adams, University of Western Australia, AustraliaView Bio |
09.20 pm to 09.45 pm |
| Q&A | 09.45 pm to 10.00 pm |
September, 2026
3
| Programme | Time (SGT) |
|---|---|
| Advanced Liver Diseases | |
| Opening comments and Introduction – Adj A/Prof Lee Guan Huei National University Health System, Singapore View Bio |
06.30 pm to 06.45 pm |
| “Alcohol-related liver disease and transplantation in the Asia-Pacific: practical lessons from an Australian national transplant programme” Dr. Anastasia Volovet, Sydney Local Health District, Australia View Bio |
06.45 pm to 07.10 pm |
| “MetALD in Singapore: building a clinic pathway—non-invasive risk stratification, multidisciplinary care, and when to escalate” Dr. Benjamin Nah, National University Hospital, Singapore View Bio |
07.10 pm to 07.35 pm |
| “Treating Alcohol Use Disorder as core liver care: pharmacotherapy,relapse prevention, and shared-care models between hepatology and addiction services” Dr. Charles Mak, IMH/NAMS, Singapore View Bio |
07.35 pm to 08.00 pm |
| Q & A Session | 08.00 pm to 08.20 pm |
| Break | 08.20 pm to 08.30 pm |
| “ALD and liver transplantation: from early LT for severe AAH to long-term outcomes—what systems must change” Prof. Sumeet K. Asrani Baylor Simmons Transplant Institute Dallas, Texas, USA View Bio |
08.30 pm to 08.55 pm |
| Update on the diagnosis and treatment of MetALD Prof. Maja Thiele, University of Southern Denmark View Bio |
08.55 pm to 09.20 pm |
| Q & A Session | 09.20 pm to 09.35 pm |
| Close | 09.35 pm |